Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial

Stroes, Erik S.G.; Сусеков, А. В.; Bruin, T.W.A. de; Kvarnström, Mats; Hong, Yun–Chul; Davidson, Michael

doi:10.1016/j.jacl.2017.10.012

Cited by 27 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The decrease of VLDL-C concentrations was similar to that of TGs. HDL-C were modestly raised by both treatments, with no extra benefit given by omega-3 [ 106 ].…”

Section: Ppar-α: Fibrates and Omega-3 Fatty Acids In The Metabolicmentioning

confidence: 99%

PPAR Agonists and Metabolic Syndrome: An Established Role?

Botta

Audano

Sahebkar

et al. 2018

IJMS

189

129

View full text Add to dashboard Cite

Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated receptors (PPARs) are involved in the metabolic regulation of lipid and lipoprotein levels, i.e., triglycerides (TGs), blood glucose, and abdominal adiposity. PPARs may be classified into the α, β/δ and γ subtypes. The PPAR-α agonists, mainly fibrates (including newer molecules such as pemafibrate) and omega-3 fatty acids, are powerful TG-lowering agents. They mainly affect TG catabolism and, particularly with fibrates, raise the levels of high-density lipoprotein cholesterol (HDL-C). PPAR-γ agonists, mainly glitazones, show a smaller activity on TGs but are powerful glucose-lowering agents. Newer PPAR-α/δ agonists, e.g., elafibranor, have been designed to achieve single drugs with TG-lowering and HDL-C-raising effects, in addition to the insulin-sensitizing and antihyperglycemic effects of glitazones. They also hold promise for the treatment of non-alcoholic fatty liver disease (NAFLD) which is closely associated with the MetS. The PPAR system thus offers an important hope in the management of atherogenic dyslipidemias, although concerns regarding potential adverse events such as the rise of plasma creatinine, gallstone formation, drug–drug interactions (i.e., gemfibrozil) and myopathy should also be acknowledged.

show abstract

“…The decrease of VLDL-C concentrations was similar to that of TGs. HDL-C were modestly raised by both treatments, with no extra benefit given by omega-3 [ 106 ].…”

Section: Ppar-α: Fibrates and Omega-3 Fatty Acids In The Metabolicmentioning

confidence: 99%

PPAR Agonists and Metabolic Syndrome: An Established Role?

Botta

Audano

Sahebkar

et al. 2018

IJMS

189

129

View full text Add to dashboard Cite

show abstract

“…Omega oils are essential fatty acid naturally present in fish, algae, and other seafood; their use as a TG-lowering drug in the management of severe HTG is recommended by both the National Lipid Association [19] and the American Heart Association [20]. The EVOLVE study found a statistically significant reduction in serum TG in patients with severe HTG treated with omega 3 oil 2 g daily in comparison with those treated with olive oil 2 g daily, with a greater treatment effect in patients with very high baseline TG concentrations [21]. The proposed mechanisms to explain these finding include decreased VLDL synthesis by altering transcription factors such as sterol regulatory element-binding proteins involved in triglyceride synthesis and increased triglyceride clearance from the serum by increased lipoprotein lipase activity [22].…”

Section: Discussionmentioning

confidence: 99%

Diabetic Ketoacidosis Revealing a Severe Hypertriglyceridemia and Acute Pancreatitis in Type 1 Diabetes Mellitus

Zaher

Boubagura

Rafi

et al. 2019

Case Reports in Endocrinology

View full text Add to dashboard Cite

Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication occurring in patients with diabetes, especially in patients with type 1 diabetes (T1D), due to an insulin deficiency. Moderate hypertriglyceridemia is commonly observed in DKA but severe hypertriglyceridemia with a triglyceride level exceeding 10g/L is very rarely reported. We report a case of a 14-year-old boy who had type 1 diabetes for 4 years treated with insulin therapy, also having adrenal insufficiency treated with hydrocortisone who presented with ketoacidosis and excruciating abdominal pain. Investigations revealed hypertriglyceridemia at 64g/L, lipasemia at 1000 U/L, and stage E pancreatitis on abdominal CT. The patient was treated with intravenous insulin, rehydration, and fenofibrate with good clinical and biological evolution. Severe hypertriglyceridemia causing pancreatitis in type 1 diabetes mellitus is a rare but very serious complication of DKA in children.

show abstract

“…Помимо этих ранних работ в научной литературе представлены результаты еще нескольких исследований, в которых применялись ω-3 ПНЖК в различных популяциях пациентов: ALPHA-OMEGA [28], OMEGA [29], SU.FOL.OM3 Study [30], ORIGIN [31], Risk and Prevention Study [32] EVOLVE-I [33], EVOLVE-II [34], ASCEND (A Study of Cardiovascular Events in Diabetes) [35], The Vitamin D and Omega-3 Trial (VITAL) [36], ECLIPSE [37], ESPRIT [38], MARINE [39], ANCHOR [40]. В ряде исследований (EVOLVE-I, II, MARINE, ACNCHOR) изучалось влияние терапии ω-3 ПНЖК на уровень ТГ и безопасность лечения, в ряде крупных рандомизированных исследований (ALPHA-OMEGA, ASCEND,ORIGIN, Risk and Prevention Study, STRENGTH) -влияние на «твердые» конечные точки.…”

Section: основные рандомизированные «исследования-интервенции» с ω-3 пнжкunclassified

“…Новая форма ω-3 ПНЖК (торговое название эпанова) -это смесь ЭПК и карбоновых кислот, зарегистрированная в США в мае 2014 г. У больных с уровнем триглицеридов 2,3-22,5 ммоль / л назначение 4 г эпановы позволяет снизить уровень ТГ на 31 % и уровень ХС-неЛВП на 9,6 % [33,34,37,38]. В исследовании ESPRIT у 627 пациентов с умеренной гипертриглицеридемией (ТГ (2,3-5,6 ммоль / л), получавших базовую терапию статинами, снижение уровня ТГ было более значительным (20,6 %), а уровня ХС-неЛВП -умеренным (6,9 %), без статистически значимых изменений концентрации ХС ЛНП и ХС ЛВП [38].…”

Section: эпанова (эпк + карбоновые кислоты дгк)unclassified

Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis

Сусеков

2021

Kardiologiia

View full text Add to dashboard Cite

Along with increased levels of low-density cholesterol, lipid factors of the risk of cardiovascular complications (CVC) include hypertriglyceridemia, particularly increased plasma levels of remnant particles. Omega-3 polyunsaturated fatty acids (ω-3 PUFA) are essential for normal functioning of cell membranes, retina, nerve tissue, skeletal muscles, etc. Among the large family of fatty acids (FA), eicosapentaenoic (EPC) and docosahexaenoic (DHX) FA are most studied. The beneficial effect of ω-3 PUFA consumption on the cardiovascular system is related with improvement of blood rheology, antiarrhythmic and anti-inflammatory effects, and a decrease in triglycerides. Large randomized studies of ω-3 PUFA (mixed EPC and DHX or only EPC) have demonstrated their efficiency and safety and a capability for reducing the incidence of CVC and sudden death as well as improvement of the prognosis in various patient populations. In the STRENGTH study (combination of omega-3 and statins), no significant decrease in the risk of CVC was achieved in patients with high triglycerides and low high-density lipoproteins. The ω-3 PUFA treatment is regulated by current international Guidelines and Consensuses as a part of combination therapy with statins for reduction of the risk of CVC and correction of pronounced hypertriglyceridemia.

show abstract

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial

Abstract: An intermediate dose of OM3-CA (2 g daily) significantly lowers TG and non-high-density lipoprotein cholesterol concentrations in patients with SHTG and may benefit individuals at risk of acute pancreatitis and cardiovascular disease.

Cited by 27 publications

References 23 publications

PPAR Agonists and Metabolic Syndrome: An Established Role?

PPAR Agonists and Metabolic Syndrome: An Established Role?

Diabetic Ketoacidosis Revealing a Severe Hypertriglyceridemia and Acute Pancreatitis in Type 1 Diabetes Mellitus

Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis

Contact Info

Product

Resources

About